A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term ...

Most hospitalized COPD flare-ups aren't severe by bedside criteria, experts say, and a tiered testing bundle could guide ...

The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election require ...

Interleukin 33 (IL-33) biology differs from type 2 (T2) inflammation in ways that could allow biologic therapy to reach patients with chronic obstructive pulmonary disease (COPD) regardless of blood ...

Senator Andy Kim (D, New Jersey) discusses plans to reverse Medicaid cuts and make caregiving a priority in the next Congress ...

Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded ...

Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap ...

Clinicians at Population Health Roundtables shared obesity care innovations, from pharmacist-led models to same-day liver ...

Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.

Parvez Mantry, MD, shares real-world resmetirom data from AASLD 2026, including GLP-1 combination use and biopsy-sparing monitoring.

SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.

Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and ...